EIF4EBP1 and colorectal cancer: In conclusion, our study suggests that pharmacological inhibition of an upstream mTORC1 activator such as PAT4 in colorectal cancer could complement the actions of rapamycin, by blocking a rapamycin-resistant, 4E-BP1-selective pathway.